Benzothiazol compounds and methods using the same for treating neurodegenerative disorders

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is cyclopropyl, cyclobutyl, or 3- or 4-membered heterocyclyl, wherein R1 is optionally substituted with one or more groups selected from the group consisting of halo, alkyl, hydroxyalkyl and haloalkyl,
• R2 and R3 are independently —H, halo, alkyl, alkoxy, —CF3, or —OCF3,
• R4 is aryl, heteroaryl, cycloalkyl, heterocyclyl, or heteroalkyl, wherein R4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, trimethylsilylethoxymethyl, —NO2, —NRaRb, —NRaC(═O)Rb, —NRaC(═O)NRaRb, —NRaC(═O)ORb, —ORa, —CN, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, —OC(O)Ra, —OC(═O)ORa, —OC(═O)NRaRb, —SRa, azetidinyl, oxetanyl, tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl, oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl, and Ra and Rb are independently —H, halo, amino, alkyl, or haloalkyl.